Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 71 results for parkinson

  1. Combination treatment for Parkinson's disease dementia:- What is the effectiveness of combination treatment with a cholinesterase inhibitor and memantine for people with Parkinson's disease dementia if treatment with a cholinesterase inhibitor alone is not effective or no longer effective?

    Recommendation ID NG71/1 Question Combination treatment for Parkinson's disease dementia:- What is the effectiveness of combination...

    Research recommendation
    Published
    15 October 2018

  2. Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)

    This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.

    NICE guideline
    Published
    15 October 2025

    Sections for NG252

  3. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

    NICE guideline
    Last updated
    2 October 2023

    Sections for NG127

  4. Physiotherapy:- Does physiotherapy started early in the course of Parkinson's disease, as opposed to after motor symptom onset, confer benefits in terms of delaying symptom onset and/or reducing severity?

    Physiotherapy:- Does physiotherapy started early in the course of Parkinson's disease, as opposed to after motor symptom onset, confer...

    Research recommendation
    Published
    15 October 2018

  5. Falls (QS86)

    This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:

    Quality standard
    Last updated
    29 April 2025
    View quality statements

    Sections for QS86

  6. Orthostatic hypotension treatment:- For people with Parkinson's disease, what is the most effective pharmacological treatment for orthostatic hypotension?Particular interventions and comparisons of interest are:- midodrine compared with fludrocortisone (primary comparison)- pyridostigmine- ephedrine - pseudoephedrine.

    Question Orthostatic hypotension treatment:- For people with Parkinson's disease, what is the most effective pharmacological treatment...

    Research recommendation
    Published
    15 October 2018

  7. Further research on unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease, which could include randomised controlled trials, should address patient selection and report on long-term follow-up.

    MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease, which could include randomised...

    Research recommendation
    Published
    13 November 2018

  8. Rapid eye movement sleep behaviour disorder treatment:- What is the best first-line treatment for rapid eye movement sleep behaviour disorder (RBD) in people with Parkinson's disease?

    for rapid eye movement sleep behaviour disorder (RBD) in people with Parkinson's disease? Any explanatory notes(if applicable) Why this...

    Research recommendation
    Published
    15 October 2018

  9. Transient loss of consciousness ('blackouts') in over 16s (CG109)

    This guideline covers assessment, diagnosis and referral for people over 16 who have had a transient loss of consciousness (TLoC; also called a blackout). It aims to improve care for people with TLoC by specifying the most effective assessments and recommending when to refer to a specialist.

    Clinical guideline
    Last updated
    21 November 2023
    View recommendations

    Sections for CG109

  10. Extradural motor cortex stimulation (EMCS) for Parkinson's disease

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  11. Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

    Awaiting development Reference number: GID-TA10773 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

    General practice indicators suitable for use in QOF
    Published
    31 July 2019

  13. How much using remote monitoring devices to guide decisions about care affects symptoms, and therefore health-related quality of life, is uncertain. How long after using the devices any impact would last is also uncertain. This had a sizeable influence on cost-effectiveness estimates (see section 3.10 ). Data on this came from studies that did not represent likely NHS practice (see section 3.6 ), which is itself uncertain (see section 3.3 ), and from assumptions made by the EAG because of lack of data. For its model, the EAG used a published algorithm from Chandler et al. (2020) to estimate quality-adjusted life years (QALYs) from the Unified Parkinson's Disease Rating Scale (UPDRS) domain scores. The clinical experts said that health-related quality of life questionnaires like the PDQ‑39 are increasingly used in trials to assess health-related quality of life for people with Parkinson's disease. The committee also recognised that the effect of the devices on the health-related quality of life of carers had not been included in the EAG's model because of a lack of data (see section 3.13 ).

    (2020) to estimate quality-adjusted life years (QALYs) from the Unified Parkinson's Disease Rating Scale (UPDRS) domain scores. The...

    Research recommendation
    Published
    7 March 2023

  14. Delirium in adults (QS63)

    This quality standard covers the prevention, diagnosis and management of delirium in adults (aged 18 and over) in hospital or long-term care settings (such as residential care or nursing homes). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    24 July 2014
    View quality statements

    Sections for QS63

  15. Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)

    This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.

    Clinical guideline
    Last updated
    18 January 2023
    View recommendations

    Sections for CG103